Trials / Terminated
TerminatedNCT02923531
Addition of X4P-001 to Nivolumab Treatment in Participants With Renal Cell Carcinoma
A Phase 1B/2A Trial Adding X4P-001 in Patients Receiving Nivolumab for Treatment of Advanced Clear Cell Renal Cell Carcinoma
- Status
- Terminated
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 9 (actual)
- Sponsor
- X4 Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine if the combination of X4P-001 plus nivolumab is safe and tolerable. Secondly, the study will investigate if adding X4P-001 to nivolumab treatment has an effect on the body and the cancer tumor, in participants receiving nivolumab but not exhibiting a radiological response.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | X4P-001 | X4P-001 will be administered as per the dose and schedule specified in the arm. |
| DRUG | Nivolumab | Nivolumab will be administered as per the dose and schedule specified in the arm. |
Timeline
- Start date
- 2016-12-07
- Primary completion
- 2018-08-08
- Completion
- 2018-08-08
- First posted
- 2016-10-04
- Last updated
- 2022-12-29
- Results posted
- 2022-12-29
Locations
4 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02923531. Inclusion in this directory is not an endorsement.